Study to Evaluate the Efficacy and Safety of CardiolRx™ in Patients With COVID-19 and Cardiovascular Disease or Risk Factors A Double-blind, Placebo-controlled Trial
Latest Information Update: 16 Dec 2022
Price :
$35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Cardiol Therapeutics
- 12 Dec 2022 Status changed from recruiting to discontinued.
- 21 Jul 2022 Planned End Date changed from 1 Dec 2022 to 31 Aug 2023.
- 21 Jul 2022 Planned primary completion date changed from 1 Nov 2022 to 30 Jun 2023.